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Background: Xenotransplantation using porcine cells, tissues or organs may be associated with the 
transmission of porcine endogenous retroviruses (PERVs). More than 50 viral copies have been 
identified in the pig genome and three different subtypes of PERV were released from pig cells, two of 
them were able to infect human cells in vitro. RNA interference is a promising option to inhibit PERV 
transmission.  
 
Methods: We recently selected an efficient si (small interfering) RNA corresponding to a highly 
conserved region in the PERV DNA, which is able to inhibit expression of all PERV subtypes in PERV-
infected human cells as well as in primary pig cells. Pig fibroblasts were transfected using a lentiviral 
vector expressing a corresponding sh (short hairpin) RNA and transgenic pigs were produced by 
somatic nuclear transfer cloning. Integration of the vector was proven by PCR, expression of shRNA 
and PERV was studied by in-solution hybridization analysis and real-time RT PCR, respectively.  
 
Results: All seven born piglets had integrated the transgene. Expression of the shRNA was found in all 
tissues investigated and PERV expression was significantly inhibited when compared with wild-type 
control animals. 
 



































Xenotransplantation using porcine cells, tissues or organs may offer a potential solution for the 
shortage of allogeneic human organs [1]. Pigs are the most favored donor species for several reasons: 
(i) similar physiology and size of organs, (ii) unlimited availability, (iii), short generation interval, high 
number of progeny (up to 15 to 18 piglets); (iv) relatively low costs, (v) maintenance under high 
hygienic conditions is possible, i.e., specified pathogen-free (spf) breeding and gnotobiotic delivery is 
possible, (vi) tools for the genetic modification to reduce the immunogenicity are available and (vii) 
somatic cloning is possible and thus production of transgenic animals can be significantly enhanced 
[2]. However, prior to the clinical use of porcine xenotransplants, three main hurdles have to be 
overcome: The immunological rejections, the physiological incompatibility and the risk of transmission 
of porcine pathogens. The premier immunological hurdle, the hyperacute rejection, which is due to the 
stimulation of the human complement system through the gal alpha 1,3 gal epitopes on the surface of 
porcine cells can be overcome in a clinically acceptable manner by either the production of Gal knock-
out animals [3,4] or animals over-expressing human complement regulatory factors [5].  
 
Specified pathogen-free breeding of pigs can prevent transmission of most porcine microbes. 
However, porcine endogenous retroviruses (PERVs) are integrated in the porcine genome [6,7], and 
can be released as infectious particles from normal pig cells [8–10] and can infect human cells in vitro 
[11– 15]. The three replication-competent subtypes of PERVs mainly differ in their receptor-binding 
site of the envelope protein [6,16]. The subtypes PERVA and PERV-B are polytropic and able to infect 
human cells in vitro, whereas the ecotropic PERVC infects only porcine cells.  
Retroviruses are tumorigenic and may cause immunodeficiencies in infected hosts. The risk of PERV 
infection has to be carefully assessed specifically in view of the fact that the human immunodeficiency 
viruses HIV-1 and HIV-2, causing AIDS in humans, are the result of multiple trans-species 
transmissions of retroviruses from non-human primates [17,18]. However, in several clinical 
applications of porcine islet cells or ex vivo perfusions of pig liver cells such as bridging during acute 
liver failure, no virus transmission could be detected [19–22]. Likewise, in a cohort of 160 patients 
treated with various porcine tissues, no PERV transmission was observed [23,24]. Moreover, PERV 
transmission was not found after pig to non-human primate transplantation and PERV infection 
experiments [25–27]. However, the risk of PERV transmission associated with tumors or 
immunodeficiencies is still prevalent [28]. Removal of PERV sequences by knock-out technology 
would be the safest strategy, but may prove difficult due to the presence of numerous replication 
competent and defective proviruses capable of recombination and complementing each other.  
 
Different strategies for the prevention of PERV transmission have been developed including the 
selection of low-producer animals based on sensitive PERV assays [29–31], the generation of an 
antiviral vaccine [32], and the inhibition of PERV expression by RNA interference (RNAi) [33–35]. In 
these first experiments efficient short interfering RNAs (siRNAs) were selected and inhibition of virus 
expression was studied in PERV infected human cells [33] and primary pig cells [36].  
 
The mechanism of RNAi is highly conserved among different biological systems, including plants, flies, 
worms, and mammals [37]. After processing by the ribonuclease III-like enzyme Dicer, double 
stranded RNA is cleaved into small double stranded fragments (21 to 25 nt) [38]. In the cytoplasm, 
these siRNAs interact with the RNA induced silencing complex, which recognizes the target mRNA, 
that is homologous to the sequence of the siRNA. Nucleases, which are part of the complex, degrade 
the target RNA and prevent protein translation [39,40]. Transfection of mammalian cells with longer 
dsRNA (>30 nt) induced an interferon response associated with an unspecific degradation of mRNA 
and finally apoptosis. The Dicer processing step can be bypassed by transfecting cells with synthetic 
siRNAs [41]. The amount of siRNAs within the 
cells is diluted out during cell division, thus limiting the time of gene silencing activity to approximately 
four to eight cell doublings [42,43]. Expression of sh (short hairpin) RNAs, that contain a short loop 
sequence linking the forward and reverse strand, can overcome this limitation. Defined shRNA without 
any cap- or polyAstructure can be expressed by polymerase-IIIdependent promoters such as the 
murine or human U6 snRNA- or the human RNase P (H1) RNA-promoters [44–47]. In addition, cells 
with stable chromosomal integration and permanent inhibition of target genes can be obtained if 
adequate selection markers are used. In addition, retroviral vectors may be used to integrate the 
siRNA producing vector [36]. The efficacy of RNAi has been investigated in vivo, until now mainly in 
mice, rats, and cattles [48–52].  
 
Here, we show for the first time lentiviral vectormediated RNAi in pigs associated with a significant 
inhibition of PERV expression.  
  
Materials and methods 
 
Cell culture and lentiviral transfection 
 
Primary pig fibroblasts were transduced with the lentiviral vector pLVTHM-pol2 (Fig. 1). The vector 
expressed a shRNA corresponding to the viral pol2 sequence able to inhibit PERV expression 
efficiently [36]. Transduced cells were grown as described [53], selected by FACS using the 
expression of the reporter gene GFP and used in nuclear transfer.  
 
Generation of transgenic pig embryos by somatic nuclear transfer  
 
Transgenic pigs were generated by somatic nuclear transfer cloning using in vitro matured abattoir 
oocytes [54]. Briefly, oocytes were enucleated by removing the first polar body along with adjacent 
cytoplasm containing the metaphase plate. The donor cells were arrested at G0/G1 of the cell cycle 
by contact inhibition and serum starvation [DMEM + 0.5% fetal calf serum (FCS)] for 48 h. Prior to 
nuclear transfer, cells were treated for 10 min with trypsin/EDTA and centrifuged (200 g/3 min) twice in 
a 10 ml tube containing 5 ml phosphate-buffered saline and 100 ll FCS. The supernatant was removed 
and the cells were resuspended in Ca2+-free TL-HEPES medium. A small fibroblast from the positive 
cell clone was placed in the perivitelline space in close contact with the oocyte membrane to form a 
couplet. After cell transfer, fusion was induced in Ca2+-free SOR2 medium [0.25 m Sorbitol, 0.5 mm 
Mg-acetate, 0.1% bovine serum albumin (BSA)]. A single electrical pulse of 15 V for 100 ls (Eppendorf 
Multiporator_, Eppendorf, Germany) between two electrodes was employed to fuse the membranes 
of the oocyte and the donor cell. The reconstructed embryos were activated in an electrical field of 1.0 
kV/cm for 45 ls in SOR2 activation medium (0.25 m Sorbitol, 0.1 mm Ca-acetate, 0.5 mm Mg-acetate, 
0.1% BSA) followed by incubation with 2 mm 6-dimethylaminopurine (DMAP; Sigma, Steinheim, 
Germany) in NCSU23 medium for 3 h prior to transfer to recipients. 
 
 
Synchronization of recipients and embryo transfer 
 
Peripuberal German Landrace gilts served as recipients. The gilts were synchronized by feeding 20 
mg/pig Altrenogest (Regumate_; Janssen-Cilag, Neuss, Germany) for 13 days followed by an injection 
of 1000 IU Pregnant Mare Serum Gonadotropine (PMSG; Intergonan_, Intervet, Unterschleissheim, 
Germany) on the last day of Altrenogest feeding. Ovulations were induced by intramuscular injections 
of 500 IU human Chorion Gonadotropin (hCG; Ovogest_, Intervet) 80 h after PMSG administration. 
Nineteen hours later, 115 reconstructed embryos were surgically transferred into the oviducts of one 
recipient via mid ventral laparatomy under general anesthesia induced and maintained with thiopental 
sodium (Trapanal_, Altana, Konstanz, Germany). Maintenance of pregnancies was supported by 
administration of 1000 IU PMSG and 500 IU hCG on days 12 and 15 after surgery. Pregnancy was 





DNA was isolated from ear biopsies using a salt chloroform extraction method. Sixty micrograms 
tissue were incubated in 500 ll HOM buffer (160 mm saccharose, 80 mm EDTA, 100 mm Tris–HCl pH 
8.0) (all reagents in this chapter from Roth, Karlsruhe, Germany) and 20 ll of a proteinase K solution 
(20 mg/ml; Invitrogen, Karlsruhe, Germany) at 60 _C over night. After addition of 200 ll of a 4.5 m 
NaCl solution and 700 ll chloroform/isoamyl alcohol, DNA was extracted by centrifugation (10 min, 10 
000 g, 4 _C). The aqueous phase containing genomic DNA was mixed with 700 ll isopropanol and 
centrifuged as described above. After washing with 70% (v/v) ethanol the precipitated DNA was 
resuspended in 70 ll H2O and stored at )20 _C until assayed. 
 
 
Detection of transgene 
 
Integration of the transgene was investigated by two independent PCR assays, using primers 
specific for (i) GFP (GFP for: 5¢-GATCACGAGACTAGCCTCGAGGT, GFP rev: 5¢-
CCAGGATGTTGCCGTCCTC) and (ii) the shRNA expression cassette (pol2 for: 5¢-
AACGCTGACGTCATCAAC, pol2 rev: 5¢-GGACGCTGACAAATTGAC) under the following 
temperature conditions: 95 _C, 10 min; 35 cycles (95 _C, 30 s; 45 _C and 54 _C respectively, 30 s; 72 
_C, 1 min); 72 _C, 5 min. 
  
Isolation of siRNA and total RNA 
 
The siRNA and siRNA-depleted total RNA isolation from frozen tissues was carried out using the 
mirVana miRNA isolation Kit (Ambion, Huntingdon, UK) allowing the enrichment of RNAs smaller than 
200 nucleotides according to the manufacturer’s instructions and stored at )80 _C until assayed. 
 
 
RNA probe construction  
 
For the in liquid hybridization a short 32P (GE Healthcare, Freiburg, Germany)-labeled RNA 
probe (29 nt) was generated by in vitro transcription using the mirVana miRNA Probe Construction Kit 
(Ambion). A DNA oligonucleotide with the reverse complement sequence of the targetRNAwas used 
as template for the in vitro transcription (pol2- siRNA) and an additional T7 promotor sequence 
(5¢-CCTGTCTC-3¢) on it’s 3¢end was used (5¢-AGTCAATTTGTCAGCGTCCcctgtctc- 3¢). The 
transcription reaction and the gel purification of the labeled probe were performed according to the 
manufacturer’s instructions. Visualization was carried out by phosphor-imaging (Imagine Plate Type 
Bas-III and FLA-2000; Fujifilm, Düseldorf, Germany) with an exposition time of 30 to 60 s. 
 
 
Detection of siRNA 
 
Pol2-siRNA was detected with the mirVana miRNA Detection Kit (Ambion) according to the 
manufacture’s instructions, detection was carried out by phosphor-imaging with an exposure time of 
3 to 7 min.  
 
 
One-step RT real-time PCR  
 
Quantitative real-time RT PCR was performed 
using the SuperScript One-Step RT-qPCR System with Platinum_ Taq DNA polymerase (Invitrogen) 
and the MX4000 thermocycler (Stratagene, La Jolla, CA, USA). A FAM-labeled probe (5¢- 
FAM-AGAAGGGACCTTGGCAGACTTTCTBHQ1; Sigma) as well as primers specific for PERV 
gag, amplifying the viral full length RNA of all three subtypes (for: TCCAGGGCTCATAATTTGTC, 
rev: TGATGGCCATCCAACATCGA) were applied. PERV expression was normalized 
to the amount of total RNA as well as to the expression of the house-keeping genes glycerinaldehyd- 
3-phosphate-dehydrogenase (GAPDH), cyclophilin and hypoxanthine-guanine 
phosphoribosyltransferase (HPRT). A HEX-labeled probe 
and primers specific for porcine GAPDH (5¢-HEXCCACCAACCCCAGCAAGAGCACGC- 
BHQ1, for: 5¢-ACATGGCCTCCAAGGAGTAAGA, rev: GATCGAGTTGGGGCTGTGACT) (Operon, 
Cologne, Germany), a Cy5-labeled probe and primers specific for porcine cyclophilin (5¢-Cy5- 
TGCCAGGGTGGTGACTTCACACGCC-BHQ2, for: 5¢-TGCTTTCACAGAATAATTCCAGGATTTA, 
rev: 5¢-GACTTGCCACCAGTGCCATTA, Operon), as well as a FAM-labeled probe and primers 
specific for porcine HPRT (FAM-ATCGCCCGTTGACTGGTCATTACAGTAGCT- BHQ1, for: 5¢-
GTGATAGATCCATTCCTATGACTGTAGA, rev: 5¢-TGAGAGA TCATCTCCACCAATTACTT were 
used [55]. For each reaction, 50 ng total RNA and the following temperature conditions were used: 
50 _C, 15 min; 95 _C, 2 min; 45 cycles (95 _C, 15 s; 54 _C, 30 s). PERV expression in each organ 
was normalized to porcine GAPDH, porcine cyclophilin and total RNA, respectively, and compared 
with the expression in the corresponding organ of the control animal. Samples from control and 
experimental animals were always run together. Data were analyzed using the DDCTmethod [56]. 
 
 
Western blot analyzes 
 












shRNA-mediated inhibition of PERV expression in primary fibroblasts 
 
Porcine fetal fibroblasts (primary cell line: P1 F10) were transduced using the lentiviral vector 
pLVTHM-pol2 (Fig. 1) expressing the PERV-specific shRNA pol2. In order to analyze the 
shRNAmediated inhibition of PERV-mRNA expression, total RNA was isolated from transduced and 
nontransduced fibroblasts and one-step RT real-time PCR was performed. PERV full-length mRNA 
expression was inhibited by 94.8% in fetal fibroblasts P1 F10 transduced with pLVTHM-pol2 as 
described previously [36]. The inhibition of PERV expression in transduced cells was stable and 
remained at 95% over months. 
 
 
Somatic cell nuclear transfer and the production of shRNA transgenic pigs and control animals 
 
The pLVTHM-pol2-transduced fibroblasts were cultured in vitro prior to being used for the production 
of transgenic pigs via somatic cell nuclear transfer. After activation, 115 cloned embryos were 
transferred surgically into the oviducts of one synchronized recipient. Pregnancy was confirmed by 
ultrasound scanning on days 25 and 35 after embryo transfer. After 116 days of gestation seven 
piglets were born; one of them was stillborn. None of the piglets showed any malformations. Mean 
birth weight was 1.3 kg which is similar to that of non-transgenic piglets in our pig facility. Ear biopsies 
were obtained from six piglets and frozen in liquid nitrogen. Four piglets died soon after birth due to 
agalactia of the sow. Following repeated application of 2 ml oxytocin (Oxytocin 10 IE/ml; Pharma 
Partner, Hamburg, Germany) lactation was reinitiated and two piglets survived. They were killed by 
barbiturate overdose at day 3, and samples of heart, lungs, spleen, liver, kidney, pancreas as well 
as muscle were taken and frozen in liquid nitrogen for further analysis. Control animals were produced 
by nuclear transfer using primary fibroblasts from non-transduced porcine fibroblasts P1 F10. At day 
89 of gestation, organs of five animals were obtained by Caesarian section, the fetuses had a mean 
weight of 1.1 kg. 
 
 
Detection of vector integration 
 
To detect the presence of the transgene, the lentiviral vector pLVTHM-pol2, in the genome of 
the piglets, PCRs were performed with primers specific for gfp and specific for the shRNA expression 
cassette (Fig. 1). All of the six tested piglets were positive for gfp (piglet 1 was not tested) and the 
shRNA expression cassette (all animals were tested positive), respectively (Fig. 2). 
 
 
Expression of the pol2-shRNA in vivo 
 
For analysis of the expression of the pol2-shRNA in different organs, small RNA molecules were 
isolated from the organs of piglets no. 6 and 7 and used for Northern solution hybridization with a 
32P-labeled short RNA probe corresponding the shRNA sequence. Expression of pol2-shRNA was 
detected in all organs, including heart, lung, spleen, liver, kidney, muscle, and pancreas (Fig. 3). 
 
 
Inhibition of PERV expression in different tissues 
 
Total RNA was isolated from different organs of piglets no. 6 and 7 and analyzed using one-step RT 
real-time PCR. As control, total RNA isolated from the corresponding organs taken from five control, 
non-transgenic pigs was used. Expression of PERV in different organs of the shRNAtransgenic 
and the non-transgenic control animals was highest in the spleen and lower expression was found in 
the liver. Due to the differences in PERV expression related to individual organs, PERV expression 
was compared in shRNA-transgenic and non-transgenic animals on a per organ basis. The expression 
levels of PERV in each organ of the control pigs were averaged and set 100%. PERV-expression in 
the corresponding organs from the shRNA-pol2 transgenic piglets was related to the expression in the 
control organ. Data were normalized to the amount of total RNA or the expression of the house-
keeping genes GAPDH, cyclophilin, and HPRT. In all organs of the pol2-shRNA transgenic piglets no. 
6 and 7 PERV expression was significantly inhibited by up to 94% (Fig. 4). Irrespective of the type of 
normalization (total RNA amount or housekeeping genes GAPDH, cyclophilin, and HPRT) similar 
expression patterns were observed. Noteworthy, expression of PERV in organs of the control animals 
  
was similar to the expression of PERV in adult animals. Preliminary data showed an expression of 
2446 copies of PERV/ng in the hearts from five control animals, 500 and 492 in the hearts of the 
transgenic piglets 6 and 7, respectively. 4564 copies/ng were found in the control lungs vs. 1337 and 
936 in the lungs of the transgenic piglets 6 and 7. In the control liver 1614 copies/ng were detected vs. 
166 and 328 in the livers of the transgenic piglets, in the spleens 34068 vs. 1908 and 2419, in the 
kidneys 2532 vs. 975 and 390, showing the efficacy of the RNAi in vivo. 
 
 
Undedectibility of PERV protein expression and virus release 
 
When PERV protein expression was studied using Western blot analyses of homogenates from 
different tissues using antisera specific for different PERV proteins (p15E, p27Gag), no PERV protein 








Results of the present study demonstrate a strong and long lasting inhibition of PERV mRNA 
expression in primary porcine fibroblasts using a lentiviral vector system expressing a PERV-specific 
shRNA and use in somatic cell nuclear transfer. This is the first report demonstrating shRNAmediated 
reduction of PERV expression in shRNA-transgenic pigs in vivo. The strategy applied here could lead 
to microbiological safer porcine xenotransplants and is therefore of considerable 
medical importance. More than fifty copies of porcine endogenous retroviruses are integrated in the 
porcine genome [6,58,59], rendering conventional gene-knockout approaches not feasible and making 
RNAi a promising alternative. The RNAi approach has already been used for the in vitro inhibition of 
HIV [60–62] and other viral pathogens like hepatitis B virus (HBV) [63,64], Coxsackie virus B3 [65], 
West Nile virus [66], and transmissible gastroenteritis virus [51]. Furthermore, RNAi-mediated reduced 
HBV expression has been demonstrated in mice in vivo [67,68] by murine hydronamic tail vene 
injection. Long-term inhibition of HBV was achieved by adeno-associated vector-mediated 
RNAi [69]. RNAi was also induced by lentiviral gene transfer in transgenic mice with a long-term 
inhibition of the target gene [70]. In contrast, HIV- 1 escapes from RNAi-mediated inhibition not only 
through nucleotide substitutions or deletions in the siRNA target sequence, but also through mutations 
that alter the secondary RNA structure [71]. Resistance and/or escape from the inhibitory effects of 
RNAi are impossible in the case of PERV, since its genome behaves like a cellular gene. 
 
In future experiments, the number of integrated shRNA vectors as well as the influence on the 
expression of PERV during life time and the persistence of the shRNA expression in the next 
generation will be analyzed. The physiological role of endogenous retroviruses is unknown. Our 
results indicate that the siRNA expression did not compromise the fetal development because the 
siRNA transgenic piglets were born after a normal gestation period, with a normal birth weight and 
without malformations. Due to the sequence specificity of the RNAi mechanism and the fact that 
PERV is a retroviral sequence, off-target effects resulting in gene silencing of vital cellular proteins 
are highly unlikely. Some RNAi off-target effects have recently been reported when interfering with 
the expression of cellular target genes [72–75]. Due to the early death of the pol2-shRNA-transgenic 
piglets caused by agalactia of the sow, long-term observations of the inhibitory effect could not yet 
be made. In transgenic mice expression of the Neil1 gene, a DNA N-glycosylase, was inhibited by 
shRNA over an extended period of time in all organs [76].  
 
The detection of the inhibitory effect of the pol2- shRNA on PERV expression in vivo requires a 
suitable control, especially in the presence of a very low expression of the PERV in the non-transgenic 
founder pigs. In addition, PERV expression varies in different pig strains [9,31] as well as in different 
tissues and organs of one individuum [77,78]. Thus detailed analysis of non-transgenic pigs of the 
same strain provides only limited insight into the RNAi effects. To provide an appropriate control, pigs 
were produced by somatic cell nuclear transfer 
using the non-transfected counterparts of the identical primary cell isolate. This allowed us to compare 
PERV expression between animals and organs isolated from different donors and this comparison 
revealed a significant reduction of PERV expression in the siRNA transgenic pigs.  
 
  
Expression data were normalized both to the amount of total RNA and to the expression of different 
house-keeping genes such as GAPDH, cyclophilin, and HPRT. HPRT is considered to be a suitable 
reference gene for the analyses of gene expression in different porcine tissues and immune cells 
[79,80]. Numerous studies on GAPDH expression in humans and rodents showed changes related to 
different experimental conditions. In addition, the existence of pseudogenes for HPRT [81] and 
GAPDH [82] complicates the use of these genes as standards in RT-PCR reactions. However, 
although the expression of all house-keeping genes used here was different in different organs, 
normalization 
of PERV expression according to the expression of each of these house-keeping genes showed a 
similar inhibitory effect of PERV expression up to 95%.  
 
Based on the low expression of viral RNA also a low expression of PERV proteins was expected. In 
Western blot assays using sera specific for p15E 
and p27Gag of PERV, no protein expression was observed, neither in the non-transgenic controls nor 
in the transgenic animals. Using the same assays PERV protein expression was also not detected in 
primary PBMCs from different pig strains such as German landrace, Duroc, Schwäbisch Hällisch, 
German large white as well as crossbreeds. In PK-15 cells, producing detectable amounts of 
infectious virus particles, expression of p27Gag was detectable, but still very low and this expression 
was reduced by RNAi nearly to 100% [36]. Higher expression of p27Gag protein was observed in 
human 293 cells infected with a high titer strain of PERV, which was only partially inhibited by RNAi 
[33]. A higher expression of PERV proteins was also observed in pig melanomas and in melanoma 
cell lines [57].  
 
The absence of viral proteins in non-transgenic and transgenic pigs suggested the absence of PERV 
release. However, the low sensitivity of the Western blot assay (detection limit: 50 ng for p15E and 
100 ng for p27Gag [57] left questions open. Improving the assays using monoclonal antibodies, 
developing a sensitive immunohistochemistry analysis or using a sensitive assay to detect RT activity 
in the plasma, such as the PERT (productenhanced reverse transcriptase) assay [83] may 
help to compare protein expression and virus release in transgenic and non-transgenic animals 
more correctly.  
 
To increase the safety of porcine xenotransplants, multiple shRNAs corresponding to different regions 
of the PERV genome shall be used. The advantage of the RNAi strategy is, that the 
expression of all PERVs will be inhibited and the likelihood of recombinations or complementation 
is further decreased. Selection of PERV lowproducer pigs using methods described earlier 
[9,31] together with the production of shRNAtransgenic animals may reduce PERV expression in 
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Fig. 1. Localization of the primers specific for GFP and pol2 in the lentiviral vector pLVTHM-pol2 (LTR 
long terminal repeat, H1 polymerase III H1-RNA gene promotor, shRNA short hairpin RNA, SIN self-
inactivating element, cPPT central polypurine tract, GFP green fluorescent protein, WPRE post-
transcriptional element of woodchuck hepatitis virus, EF-1alfa elongation factor-1a promoter, tetO 
tetracycline operator, loxP locus of X-over of P1, recombination site of Cre recombinase for 







Fig. 2. (A) Integration of the lentiviral vector 
pLVTHM-pol2 in six piglets demonstrated by 
PCR analysis using primers specific for GFP, and 
(B) primers specific for the shRNA expression 
cassette, positive control (+): vector  LVTHMpol2, 
negative control ()): DNA of non-transduced 










Fig. 3. Expression of the PERV-
specific pol2-shRNA in different 
tissues of piglets no. 6 and 7. As 
positive control pLVTHM-pol2-
transduced PK-15 cells and as 
negative controls pLVTHM-
transduced and non-transduced PK-
15 cells were used. Internal negative 
controls: no target RNA (T)/ RNase 
(the single stranded probe was 
degraded by RNase treatment), no 
target RNA/ no RNase (the full-











Fig. 4. Inhibition of PERV expression in different tissues of the pol2-shRNA transgenic piglets (p) no. 6 
and 7. PERV expression in each organ of control non-transgenic animals (c) measured by one-step 
RT real-time PCR was set 100% and compared with PERV expression in the corresponding organ of 
the transgenic animals. In case of control animals the standard deviation is based on the 
measurement of PERV expression in organs from five different animals, measured in triplicate; in case 
of transgenic animals the standard deviation is based on the measurement of one organ measured in 
triplicate in two assays. Expression was normalized to the amount of total RNA, measured by one-step 
RT real-time PCR. 
  
